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A B S T R A C T
Until the three ongoing randomised controlled trials of preventive therapy are completed, there remains
a large knowledge gap about how individuals known to have been exposed to multidrug-resistant TB
(MDR-TB) should be managed. The evolving paradigms and improving outcomes from treatment of active
MDR-TB disease play in to discussions about the relative merits and importance of intensive surveillance
and/or preventive therapy for MDR-TB contacts.
© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The scale of the problem
In 2017 there were 558,000 estimated cases of multidrug-
resistant (MDR) or rifampicin resistant (RR) TB worldwide (WHO,
2018). Mathematical modelling suggests that 1.7 billion, or a
quarter of the global population, have latent tuberculosis infection
(LTBI) (Houben and Dodd, 2016). This large reservoir of potential
future TB transmission must be tackled if the global TB epidemic is
to be controlled. The risk of progression from exposure to infection
to active disease is poorly explored in MDR-TB. 90% of active
disease in MDR-TB contacts occurs within the ﬁrst two years and
nearly all within three years (Shah et al., 2014). Improved strategies
are required to advance detection and management of this ongoing
reservoir of infection (Lonnroth et al., 2013).
The individual
We begin with Juan, a 16-year-old boy on treatment for
laboratory conﬁrmed MDR-TB at an urban health centre in Peru. He
tells a tearful story of his cousin Ernesto, also an adolescent male,
who died a year earlier from an unknown progressive illness. At
post mortem, this illness was identiﬁed as MDR-TB. The two
cousins, he explains, shared a poorly ventilated bedroom in a
suburb of Lima. Not long after his cousin’s death, Juan developed
fever, cough and weight loss and was eventually diagnosed with
MDR-TB on MODS testing. Today his mother also attends the clinic.
She reports feeling unwell for several months and has recently
developed haemoptysis. She’s had a chest X-ray and is waiting for
her results. She knows what is coming.
This desperate scenario highlights important questions about the
management of individuals who have been exposed to infectious
MDR-TB within the household. As he embarks upon a prolonged
course of toxic MDR-TB treatment, with historically poor outcomes,
we are obliged to ask “Could Juan’s disease have been prevented?”.
“How likely is it that Juan acquired his infection from Ernesto?” and
would this be useful to know? “Would active surveillance of Juan’s
mother have facilitated earlier diagnosis?” “And would this improve
the likelihood of a successful treatment outcome?”
The programme
How should the National TB Control Programme approach this
problem? MDR-TB treatment places a large and disproportionate
burden on programmes so any case that can be averted is a helpful
win. In the absence of an effective post-exposure vaccine, the only
tool available to stop infection progressing to disease is preventive
therapy (PT). The alternative is close observation of contacts to
detect and effectively treat breakthrough disease at an early stage.
There are beneﬁts and drawbacks to both approaches (PT and close
surveillance), and the relative importance that one attaches to the
key knowledge gaps plays in to which strategy might be favoured.
$ The names used in the real-life case studies have been changed.
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International guidance and recommendations
What do international agencies recommend that programmes
should do? In updated 2018 guidance the World Health Organisation
(WHO) (World Health Organization, 2018) indicated that “strict
clinical observation and close monitoring for the development of active
TB disease for at least 2 years are required, regardless of the provision of
preventive treatment” whilst also stating that “in selected high-risk
household contacts [young children, the immunosuppressed] of
patients with multidrug-resistant tuberculosis, preventive treatment
may be considered based on individualised risk assessment and a sound
clinical justiﬁcation”. This conditional recommendation is acknowl-
edged as being based upon very low-quality evidence (GRADE
(World Health Organization, 2018) proﬁle tables indicate data
comparing a total of 144 PT recipients with 191 non-recipients for
prevention of MDR-TB) and requires a positive tuberculin skin test
(TST) or interferon gamma release assay (IGRA), already acknowl-
edged as a signiﬁcant bottleneck for programmes trying to
implement isoniazid PT for people living with HIV. The heteroge-
neity of the observational data brings additional uncertainty about
the regimen contents and duration. The recommendations for PT in
children are currently based on virtually absent data.
The European Centre for Disease Control (ECDC) 2012 guidance
is supportive of careful clinical follow up [6], and in selected
circumstances after thorough risk assessment, PT, whilst com-
menting that “the current evidence base does neither reject nor
support provision of preventive therapy”. There is a telling absence of
speciﬁc comment on MDR-TB in the 2018 ECDC Scientiﬁc Advice on
LTBI (ECDC, 2012).
A 2015 policy brief, summarising the consensus view of a
meeting of experts convened to review existing evidence at
Harvard Medical School Centre for Global Health Delivery-Dubai,
comes down more clearly on the side of treating latent MDR-TB
infection with PT, though stops short of deﬁning precise regimen
composition or duration (Seddon et al., 2015).
Understanding context, making sense of the evidence,
individualising risk
It is unequivocally clear that screening household contacts of an
individual recently diagnosed with infectious pulmonary TB to
detect co-prevalent active TB is one of the highest yield active case
ﬁnding strategies. This is equally true when the index case has
MDR-TB. What happens after this is where the guidance starts to
tie itself in knots.
For asymptomatic contacts of drug-susceptible TB determined
to be at high risk for progression to disease (young children and the
immunosuppressed) a TST or IGRA is performed, and if positive is
followed by a standard PT regimen. Though the risk of progression
to active disease remains greatest for the ﬁrst two years after
exposure, contacts of drug-susceptible TB are not followed up
beyond this initial interaction; the large resource investment
required for a low case yield of a readily treatable disease mandates
against it.
What then drives such a divergent approach for those exposed
to MDR-TB, in which regular surveillance for evidence of incident
disease is recommended for two years? Treatment outcomes with
standard MDR-TB therapy are historically so miserable that early
detection and treatment of MDR-TB should mitigate transmission
risk (surely true) and improve treatment outcomes (not proven)
(Harris et al., 2016). Context now becomes important, as evolving
MDR-TB treatment regimens and improved outcomes start to
redeﬁne some of the earlier premises. Indeed, avoidance of highly
toxic MDR-TB treatment with poor efﬁcacy has until recently been
a potent argument in favour of PT over surveillance — prevention
being so much better than cure.
However, after a year in which MDR-TB treatment paradigms
have been radically revised (WHO, 2019a), does the prospect of
shorter regimens for active disease, with much improved
tolerability and efﬁcacy, signiﬁcantly shift the balance towards
more conservative approaches to the MDR-exposed, such as close
observation with early intervention?
Preventive therapy
Let us consider what PT might look like
There are three ongoing randomised controlled trials (RCTs)
currently evaluating PT, which should start reporting around 2022.
All three are using a six-month regimen and following-up for
incident TB disease for 18–30 months. In Vietnam the V-QUIN trial
is comparing levoﬂoxacin with placebo amongst all MDR-TB
contacts (ANZCT Registry-Identiﬁer, 2016). The TB CHAMP trial in
South Africa compares the same two arms but only amongst
children under 5 years (ISRCTN-ISRCTN92634082, 2019). The
PHOENIx trial (at ACTG sites) is comparing delaminid with
isoniazid for all contacts of MDR-TB (ClinicalTrials.gov Identiﬁer,
2018).
Whilst the evidence from these RCTs is awaited the existing
evidence-base to guide PT is entirely observational. There are no
agents that have yet been proven to sterilize latent MDR-TB
infection and thus prevent future disease, in sharp contrast to
drug-susceptible TB. Fluoroquinolone therapy, often in combina-
tion, has been used most frequently.
Two systematic reviews of observational studies of MDR-TB
contacts with latent infection who received PT, found a non-
signiﬁcant reduction in progression to TB disease (van der Werf
et al., 2012). In an outbreak of MDR-TB in French Polynesia, widely
cited as strong observational evidence of PT effectiveness, none of
the 104 contacts identiﬁed who received PT developed disease.
Three of 15 contacts who refused PT and 15 other community
members who had not been previously identiﬁed as contacts and
had not received PT subsequently developed MDR-TB (Bamrah
et al., 2014). Notably the regimens used were all of 12 months
duration, all included either moxiﬂoxacin or levoﬂoxacin and 51%
received ethionamide or ethambutol in addition.
186 South African child (<5 years) contacts of MDR-TB with LTBI
were given triple PT for six months with oﬂoxacin, ethambutol and
high dose isoniazid as per local guidance and followed up for a
minimum of 12 months. Six developed incident TB disease, though
these six had strong risk factors including poor compliance, and six
developed grade 3 adverse events (Seddon et al., 2013). Thus
observational experience is largely of multidrug therapy for six to
twelve months, not a million miles from evolving regimens for
treatment of active MDR disease.Exciting advances in recent years
include the development of short course combination PT for drug
susceptible LTBI (12 weekly doses of rifapentine/isoniazid) should
provide stimulus and encouragement for trialling similar strate-
gies in MDR-TB.
The ﬁrst challenge to PT implementation is the requirement to
undergo LTBI testing. Global availability of TST is low and IGRA
even lower. The second challenge is presumptive attribution of
TST/IGRA reactivity to the MDR-TB index case exposure, particu-
larly in high TB burden settings where the discordance of index-
contact strains may be highly variable (WHO, 2019b) – tailoring PT
for the contact to the supposed MDR-TB index case strain
susceptibility may result in dismissal of well-tolerated agents
with proven efﬁcacy, if the source was a separate drug-susceptible
strain. Conversely, if delamanid or levoﬂoxacin prove to be
effective and well-tolerated in RCTs, then this effectiveness would
extend to drug-susceptible organisms. The third challenge is
maintaining asymptomatic healthy contacts on drug therapy,
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particularly when there is uncertainty about the cumulative dose
required for effectiveness.
Given that 90% of exposed contacts with demonstrated
immunological sensitivity (either by TST or IGRA) will never
progress to active disease, and thus have nothing to gain from PT,
administration to all close contacts exposes the majority to
unnecessary risks. The current paucity of evidence on how to target
PT is a barrier to individualised risk assessment and should be the
focus of any future work. The development of electronic
surveillance systems for MDR-TB exposed contacts is now
recommended by WHO (WHO, 2019b). An internationally agreed
minimal dataset for such systems would allow for identiﬁcation of
risk factors for developing active disease. For example, if 90% of
contacts with secondary disease reported having previously shared
a bedroom with the index case, PT could be limited to this narrower
group with close monitoring of other household contacts.
A meta-analysis reported LTBI in around half of MDR-TB
exposed household contacts, varying widely by age group and
location (Shah et al., 2014). A systematic review described TB
disease prevalence in household contacts of MDR-TB at 3.1% (Fox
et al., 2013), however in high prevalence settings this rises to 8.7%
(Shah et al., 2014). If PT is found to be effective, there will be clear
beneﬁts in high prevalence areas.
Current WHO guidelines recommend that PT be considered in
selected high-risk contacts of patients with MDR-TB, based on
“individualised risk” and “sound clinical justiﬁcation” (WHO,
2019b). By their own admission this is based on very low quality
evidence, with minimal data to guide such individualised risk
assessment. Prospective epidemiological studies, which identify
speciﬁc characteristics of contacts at increased risk of secondary
disease, are sorely lacking. Likely beneﬁciaries include children
under 5 years and those infected with HIV (Padmapriyadarsini
et al., 2018).
What then are the beneﬁts and pitfalls of active surveillance of
contacts alone, the main alternative to PT? Clearly reduced
exposure to potentially toxic therapy is desirable, particularly
since only a small minority stand to get any beneﬁt (Langendam
et al., 2013). There is some evidence for low rates of incident
disease in contacts (Fox et al., 2013), in that the numbers needed to
treat to prevent one case of active TB are high, though recent
analyses seem to lay to rest the concept that any ﬁtness cost
exerted upon M. tuberculosis strains with resistance-conferring
mutations translates into a meaningful reduction in transmissibil-
ity or ability to cause disease (Becerra et al., 2018), when compared
to drug-susceptible strains. An important argument against the
“watch and wait” approach is the speed at which severe forms of
paediatric disease progress, running the risk of development of
life-threatening incident disease in the period between surveil-
lance visits. Indeed, the nature of surveillance remains poorly
deﬁned, both in terms of optimal frequency of contact and what
that contact should entail. In addition to the between-visit risk
period, the resource implications of quarterly or biannual face-to-
face assessments and the challenge of maintaining high rates of
follow-up with otherwise healthy individuals suggest that
alternative approaches, with a smaller-footprint but higher
frequency such as telephone call consultations, may warrant
consideration.
Final thoughts
Whilst the evidence remains inadequate and insufﬁcient to
exclusively support either management approach, new cases of
MDR-TB still need to be identiﬁed and treated, with important
attention to infection control to minimise onward transmission.
The WHO advise that ‘systematic recording and reporting’ systems
should be developed to aid management of LTBI (WHO, 2019b).
There is much to learn and we should be gleaning new knowledge
from every single identiﬁed MDR-TB contact; whether they have
active, latent or no TB infection present or if they are recipients of
PT or not. Countries are implementing a myriad of different
electronic systems to enhance TB reporting and control activities,
however we propose that a harmonised minimum dataset, which
could be incorporated into MDR-TB contact screening, should be
deﬁned. This would simultaneously facilitate collation of a large
observational cohort to address questions about the optimum
surveillance approach (identifying the best combination and
frequency of screening of symptoms, radiology and microbiology)
and enable countries to monitor and evaluate their own contact
surveillance activity performance at the touch of a button. Such in-
country registries would also provide programmes with a ready-
to-go list of individuals eligible for PT if current RCTs identify a
suitable, effective regimen.
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